CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematologists, hematology-oncology fellows and other healthcare providers involved in the treatment of hematologic cancers.
  
  

  OVERVIEW OF ACTIVITY
  Multiple myeloma (MM) is a plasma cell neoplasm that accounts for approximately 12% of all hematologic cancers and carries with it one of the worst death to new cases ratios. Although MM only represented 1.8% of all new cancer cases diagnosed in the United States in 2017, practicing clinicians would be hard pressed to identify another area of oncology in which the research database — and available treatments — has evolved more rapidly over the past decade. In addition to significantly altering the natural history of MM, novel agents, including proteasome inhibitors, immunomodulatory agents and BTK inhibitors, have contributed to recent treatment gains for 2 related blood disorders — Waldenström macroglobulinemia (WM) and amyloidosis. Featuring the latest research developments along with expert perspectives, this CME activity will deliver to community-based oncology clinicians highly applicable, current clinical information delving into the individualized and multifaceted management of these disorders.
  
  LEARNING OBJECTIVES

  • Use patient and disease characteristics, including cytogenetic profile, to customize induction and maintenance therapeutic approaches in the transplant and nontransplant settings.
  • Consider available research data and other clinical factors in the best-practice selection, sequencing and combination of current and recently approved novel agents in the nonresearch care of patients with relapsed/refractory MM.
  • Design and implement a plan of care to recognize and manage side effects and toxicities associated with recently approved systemic therapies to support quality of life and continuation of treatment.
  • Develop an evidence-based algorithm for the use of stem cell transplantation, chemotherapy and/or novel targeted agents for the management of amyloidosis.
  • Consider clinical and other patient-related factors in the sequence and selection of systemic therapy for WM requiring active treatment.
  • Develop risk-adapted treatment plans for patients with smoldering MM, considering the roles of observation and active treatment.

  ACCREDITATION STATEMENT
  This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and Research To Practice. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  It is the policy of Research To Practice and Penn State College of Medicine to ensure balance, independence, objectivity and scientific rigor in all their educational programs. All faculty, planners and managers participating in this activity are required to disclose any relevant financial relationship(s) they (or spouse/partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interest. Research To Practice and Penn State College of Medicine ensured that any conflicts of interest were resolved before the educational activity occurred.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Edward A Stadtmauer, MD
  Professor of Medicine
  Leader, Hematologic Malignancies Program
  Director, Bone Marrow and Stem Cell Transplant Program
  Division of Hematology-Oncology
  Abramson Cancer Center of the University of Pennsylvania
  Philadelphia, Pennsylvania
  
  Consulting Agreements: Amgen Inc, Celgene Corporation, Janssen Biotech Inc, Novartis, Onyx Pharmaceuticals, an Amgen subsidiary, Takeda Oncology.
  
  Sarah A Holstein, MD, PhD
  Associate Professor
  Division of Oncology and Hematology
  Department of Internal Medicine
  University of Nebraska Medical Center
  Omaha, Nebraska
  
  Advisory Committee: Celgene Corporation, Takeda Oncology; Consulting Agreement: Celgene Corporation.
  
  Paul G Richardson, MD
  Clinical Program Leader
  Director of Clinical Research
  Jerome Lipper Multiple Myeloma Center
  Department of Medical Oncology
  Dana-Farber Cancer Institute
  RJ Corman Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Advisory Committee: Bristol-Myers Squibb Company, Celgene Corporation, Novartis, Takeda Oncology.
  
  Shaji K Kumar, MD
  Professor of Medicine
  Consultant
  Division of Hematology and Blood and Marrow Transplantation
  Mayo Clinic
  Rochester, Minnesota
  
  Consulting Agreements: Abbott Laboratories, Amgen Inc, Merck, Takeda Oncology; Contracted Research: Abbott Laboratories, Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Merck, Novartis, Sanofi Genzyme, Takeda Oncology.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.
  
  PENN STATE COLLEGE OF MEDICINE — Faculty and staff involved in the development and review of this activity have disclosed no relevant financial relationships.
  
  RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice and Penn State College of Medicine do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AbbVie Inc, Celgene Corporation, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Takeda Oncology.
  
  Hardware/Software Requirements:
  A high-speed Internet connection
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
  Adobe Flash Player 27 plug-in or later
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Release date: February 1, 2018
  Expiration date: February 1, 2019